Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...

Gilead Sciences has outperformed the broader market over the past year, and analysts are moderately optimistic about the ...

Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Gilead Sciences (GILD) closed at $113.03 in the latest trading session, marking a -2.73% move from the prior day. This change lagged the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw a ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences Inc. closed 4.78% short of its 52-week high of $119.96, which the company achieved on March 10th.

AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...